ID: ALA427734

Max Phase: Preclinical

Molecular Formula: C13H7ClN6O3

Molecular Weight: 330.69

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  O=C(O)c1cc2c3cc(-n4cnnc4)c(Cl)cc3[nH]c(=O)n2n1

Standard InChI:  InChI=1S/C13H7ClN6O3/c14-7-2-8-6(1-11(7)19-4-15-16-5-19)10-3-9(12(21)22)18-20(10)13(23)17-8/h1-5H,(H,17,23)(H,21,22)

Standard InChI Key:  CVQAHSMQXIWVLD-UHFFFAOYSA-N

Associated Targets(Human)

Glutamate receptor ionotropic AMPA 265 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Glutamate [NMDA] receptor 933 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Glutamate (NMDA) receptor subunit zeta 1 2166 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Glutamate receptor ionotropic, AMPA 2103 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Glutamate receptor ionotropic, kainate 722 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Glutamate NMDA receptor 6467 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Mus musculus 284745 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 330.69Molecular Weight (Monoisotopic): 330.0268AlogP: 1.11#Rotatable Bonds: 2
Polar Surface Area: 118.17Molecular Species: ACIDHBA: 7HBD: 2
#RO5 Violations: 0HBA (Lipinski): 9HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: 3.44CX Basic pKa: 1.61CX LogP: 0.73CX LogD: -2.66
Aromatic Rings: 4Heavy Atoms: 23QED Weighted: 0.57Np Likeness Score: -1.27

References

1. Varano F, Catarzi D, Colotta V, Filacchioni G, Galli A, Costagli C, Carlà V..  (2002)  Synthesis and biological evaluation of a new set of pyrazolo[1,5-c]quinazoline-2-carboxylates as novel excitatory amino acid antagonists.,  45  (5): [PMID:11855983] [10.1021/jm010995b]
2. Varano F, Catarzi D, Colotta V, Lenzi O, Filacchioni G, Galli A, Costagli C..  (2008)  Novel AMPA and kainate receptor antagonists containing the pyrazolo[1,5-c]quinazoline ring system: Synthesis and structure-activity relationships.,  16  (5): [PMID:18063372] [10.1016/j.bmc.2007.11.046]
3. Jiang X, Wu K, Bai R, Zhang P, Zhang Y..  (2022)  Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities.,  229  [PMID:34998058] [10.1016/j.ejmech.2021.114085]
4. Haghighijoo Z, Zamani L, Moosavi F, Emami S..  (2022)  Therapeutic potential of quinazoline derivatives for Alzheimer's disease: A comprehensive review.,  227  [PMID:34742016] [10.1016/j.ejmech.2021.113949]

Source